



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Telisotuzumab

Cat. No.:	HY-P99391
CAS No.:	1781223-80-0
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Telisotuzumab (ABT-700) is a human recombinant bivalent antibody, a therapeutic antibody against the hepatocyte growth factor receptor (MET) that binds c-Met with high affinity and inhibits c-Met signaling. Telisotuzumab has antitumor activity <sup>[1]</sup> .	
<b>In Vitro</b>	Telisotuzumab (ABT-700) (10 µg/mL, 24 h) inhibits the proliferation of SNU5 cells and leads to an increase in pro-apoptotic Bim and a decrease in anti-apoptotic Bcl-xL, thereby inducing apoptosis <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
<b>In Vivo</b>	Telisotuzumab (ABT-700) (i.p., 2.5-40 mg/kg, twice a week, 90 days) effectively antagonizes constitutively activated c-Met and downstream signaling, thereby inhibiting tumor growth in SCID mice with Hs746T cells <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	SCID mice with Hs746T cells <sup>[1]</sup>
	Dosage:	2.5-40 mg/kg
	Administration:	i.p., twice a week, 90 days
	Result:	Reduced total and phosphorylated c-Met as well as phosphorylated Akt and Erk. Complete tumor regression at doses above 10 mg/kg but no effective inhibition of tumor growth at doses below 5mg/kg.

### REFERENCES

[1]. Jieyi Wang, et al. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification. BMC Cancer. 2016 Feb 16;16:105.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA